By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

Key Statistics

Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO


Company News
In the Hot CAR-T Market, Analyst Projects Juno (JUNO) Stock to Double 8/20/2015 6:41:26 AM
Juno (JUNO) Reports Second Quarter 2015 Financial Results 8/13/2015 11:57:33 AM
Juno (JUNO) To Report Second Quarter 2015 Financial Results On Wednesday, August 12 8/6/2015 10:53:16 AM
Juno (JUNO) Announces Early HSR Clearance For Global Collaboration With Celgene (CELG) 8/5/2015 7:15:44 AM
Juno (JUNO) CEO: "Can Our Own T-Cells Eat A Solid Tumor? The Answer Is Yes" 7/31/2015 7:15:10 AM
FDA OKs Juno (JUNO)'s IND for Lead Leukemia Candidate JCAR015 7/31/2015 6:01:48 AM
Step Aside Juno (JUNO): World's Richest Doctor Pulls Off Largest Biotech IPO Ever 7/29/2015 7:17:36 AM
Partnership and Acquisition Rumors in the CAR-T Cancer Space Finger Juno (JUNO), Kite Pharma (KITE) and bluebird bio (BLUE) 7/16/2015 6:23:27 AM
Celgene (CELG) Paid $93 Per Share For Juno Therapeutics (JUNO), But You're Only Willing To Pay $50? 7/9/2015 6:43:39 AM
EXCLUSIVE: Juno Therapeutics (JUNO)/Celgene (CELG) Deal "Great Validation" for Cellular Therapy, TxCell CEO Tells BioSpace (DHX) 7/1/2015 10:56:17 AM